Metformin also enhances the fluidity of cell membranes (Marc et al., 2014) and inhibits the inflammatory process by increasing plasma fibrinolytic activity, reducing the concentration of plasminogen activator inhibitor-1 (PAI-1), preventing excessive activation of platelets, and reducing endothelial damage (Hirsch et al., 2013; Bai and Chen, 2021), and these properties were proven during clinical trials among T2DM and metabolic syndrome patients. This evidence concerns the gene SERPINE1 and metabolic syndrome.